Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Adimmune Plans to Sell its Flu Vaccine in China This Year

publication date: Jan 7, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Adimmune of Taiwan has completed a China Phase III trial of its trivalent flu vaccine in 1,200 people. It expects CFDA approval in mid-2014, which will allow the company to market the vaccine in mainland China in time for the 2014-2015 flu season, making it the first Taiwanese company to provide a vaccine to China. Adimmune is the only GMP-certified vaccine maker in Taiwan. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors